Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Covid19 SARS-Associated Coronavirus Patients over 18 years old with the ability to provide free and informed consent 2. Acute Flu-Like symptoms < 07 days. 3. All patient need to have at lease ONE enhancement factor: 1. Age > 50 years; 2. Diabetes mellitus requiring oral medication or insulin 3. Systemic arterial hypertension requiring at least 01 oral medication for BP control; 4. Known cardiovascular diseases (heart failure, congenital heart disease, valvar heart valve disease, coronary artery disease, cardiomyopathies) 5. Symptomatic lung disease (emphysema, chronic bronchitis) 6. Symptomatic asthma patients requiring chronic use of agents for control of symptoms. 7. Smoking 8. Obesity, defined as BMI> 30 kg / m2 body weight 9. Transplanted patients 10. Patient with stage IV chronic kidney disease or on dialysis. 11. Immunosuppressed patients / using corticosteroid therapy (equivalent to at least 10 mg of prednisone per day) and / or immunosuppressive therapy) 12. Patients with a history of cancer in the last 05 years or undergoing treatment of a current cancer 13. Chronic renal disease KDIGO IV or End-Stage Renal Disease on chronic ambulatory renal replacement therapy 4. Patient with positive rapid test for SARS-CoV2 antigen performed on occasion of the screening or patient with a positive SARS-CoV2 diagnostic test within 07 days of the onset of symptoms. 5. Willingness to use the proposed investigative treatment and follow the protocol-related procedures foreseen in the research  Negative SARS-CoV2 test. 2. Flu-like symptom onset 08 days or more. 3. Patients with COVID-19 being referred for hospitalization; 4. Patients with history of SARS-CoV-2 vaccine shot; 5. Patients with acute respiratory conditions due to other causes; 6. Dyspnea secondary to other acute and chronic respiratory causes or infections (eg: Decompensated COPD, acute bronchitis, pneumonia, primary pulmonary arterial hypertension) 7. Acute Flu-Like condition presenting with at least ONE of the below: 1. Respiratory Rate> 28 / min; 2. SaO2 <90% or <93% in nasal oxygen therapy at 10 l / min; 3. PaO2 / FIO2 <300 mmHg 8. Patients using serotonin reception inhibitors (Donepezil, Sertraline) 9. Use of the following medications in the last 14 days: 1. Monoamine Oxide Inhibitors (MAOIs): Phenelzine, Tranylcypromine, Selegiline, Isocarboxazide, moclobemide; 2. Use of iodinated contrasts during start of treatment through D14; 3. Use of antiretroviral agents 10. Patients with severe psychiatric disorders or major uncontrolled depression or controlled with any of the prohibited drugs (see above); 11. Pregnant or breastfeeding patients; 12. History of severe ventricular cardiac arrhythmia (ventricular tachycardia, patients with ventricular fibrillation recovered) or Long QT Syndrome; 13. History of diabetic ketoacidosis or clinical condition that maintains persistent acidosis 14. Surgical procedure or use of contrast designed to occur during treatment or up to 04 days after the last dose of the study medication; 15. Current daily and / or uncontrolled alcoholism; 16. History of seizures in the last month or uncontrolled medical condition; 17. Clinical history of Liver Cirrhosis or Child-Pugh C classification; 18. Patients with known severe degenerative neurological diseases and / or diseases serious mental disorders; 19. Inability of the patient or representative to give consent or adhere to the procedures proposed in the protocol; 20. Known hypersensitivity and / or intolerance to Fluvoxamine, Ivermectin or Metformin; 21. Inability to take oral or sublingual medications; 22. Inability to follow protocol-related procedures